Our reports provide an independent, expert view supported by robust and innovative data interrogation and analysis.

Sort by:
Global Women’s Health Drugs Market to 2024 – Influx of New Products Including Orilissa, Relugolix and Bremelanotide to Diversify Landscape and Drive Growth

Published: Jan-2019

The women’s health therapy area covers medical disorders that affect females only, primarily disorders of the female.....

$4995
More Info
Global Rheumatic Disorders Drugs Market to 2024 – Increased Uptake of IL Inhibitors and JAK Inhibitors to Drive Growth as TNF Inhibitors Face Patent Expiry

Published: Jan-2019

The rheumatic disorder therapy area is multi-disciplinary in nature and encompasses conditions that affect joints, connective.....

$4995
More Info
Emerging Gene Therapies – Trends within the Technological, Clinical, Regulatory and Competitive Landscape

Published: Jan-2019

GBI Research’s latest report “Emerging Gene Therapies – Trends within the Technological, Clinical, Regulatory.....

$2995
More Info
Global Biosimilars Market – Increasingly Lucrative Market Fueled by Constrained Payer Environment and Patent Expiries for Best-Selling Biologics

Published: Jan-2019

GBI Research’s latest report: “Biosimilars” provides an in-depth assessment of the current developments.....

$2995
More Info
Global Clinical Trials – Current Trends and Recent Advancement

Published: Jan-2019

GBI Research’s latest report, Global Clinical Trials—Current Trends and Recent Advancement, provides.....

$2995
More Info
Global Dermatology Drugs Market to 2024 – IL Signaling Inhibitors to Overtake TNF-a Inhibitors as Leading Commercial Drug Class with Dupixent and Cosentyx among Key Performers

Published: Dec-2018

Dermatological conditions, diseases of the skin, hair and nails, are one of the most common types of disorders worldwide,.....

$4995
More Info
Nonalcoholic Steatohepatitis Therapeutics in Asia-Pacific Markets to 2024 – Launch of NASH-Specific Premium Products and Rising Prevalence to Drive the Market

Published: Dec-2018

Non-alcoholic steatohepatitis (NASH) is the severe form of non-alcoholic fatty liver disease (NAFLD), characterized by.....

$4995
More Info
Renal Diseases Drug Development Pipeline Review, 2018

Published: Dec-2018

This report provides an overview of the pipeline landscape for renal diseases. It provides comprehensive information on.....

$3995
More Info
Gastrointestinal Diseases Drug Development Pipeline Review, 2018

Published: Dec-2018

This report provides an overview of the pipeline landscape for gastrointestinal diseases. It provides comprehensive information.....

$3995
More Info
Innovation Tracking Factbook 2018: An Assessment of the Pharmaceutical Pipeline

Published: Dec-2018

GBI Research’s latest report “Innovation Tracking Factbook 2018: An Assessment of the Pharmaceutical Pipeline”.....

$2995
More Info
Sort by: